Decision on Rights Offering via Debt-to-Equity Swap Following Rehabilitation Plan Approval (Debt Repayment Purpose, Expected Change of Largest Shareholder)
- UNION KOREA PHARM received court approval for a rehabilitation plan on May 12, 2026.
- Sequentially implementing debt-to-equity swap (effective May 19), capital reduction/merge (May 27), and third-party allotment rights offering (May 28) per the plan.
- The rights offering is for debt repayment via debt-to-equity conversion, not new capital raising.
- Expected change of largest shareholder.
- No new cash injection; in-kind contribution is debt repayment.
- Fractional shares will be cancelled; total shares and capital may change.
- Listing date of new shares subject to change based on court decisions and procedures.
ADVERTISEMENT (250px+)
KOSDAQ Filing Information
- Filing: Report On Major Matters (Decision On Paid-In Capital Increase)
- Company: UNION KOREA PHARM (080720)
- Submission: UNION KOREA PHARM CO.,Ltd
- Receipt: 05-19-2026